Singapore markets open in 6 hours 20 minutes
  • Straits Times Index

    3,064.54
    +5.93 (+0.19%)
     
  • S&P 500

    4,472.49
    -8.21 (-0.18%)
     
  • Dow

    34,750.31
    -64.08 (-0.18%)
     
  • Nasdaq

    15,160.54
    -0.99 (-0.01%)
     
  • BTC-USD

    47,556.23
    -383.12 (-0.80%)
     
  • CMC Crypto 200

    1,221.02
    -12.26 (-0.99%)
     
  • FTSE 100

    7,027.48
    +10.99 (+0.16%)
     
  • Gold

    1,756.10
    -38.70 (-2.16%)
     
  • Crude Oil

    72.62
    +0.01 (+0.01%)
     
  • 10-Yr Bond

    1.3330
    +0.0290 (+2.22%)
     
  • Nikkei

    30,323.34
    -188.37 (-0.62%)
     
  • Hang Seng

    24,667.85
    -365.36 (-1.46%)
     
  • FTSE Bursa Malaysia

    1,555.26
    -0.25 (-0.02%)
     
  • Jakarta Composite Index

    6,109.94
    -0.29 (-0.00%)
     
  • PSE Index

    6,968.43
    +88.23 (+1.28%)
     

Organogenesis (ORGO) Stock Jumps 7.7%: Will It Continue to Soar?

  • Oops!
    Something went wrong.
    Please try again later.
·2-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Organogenesis (ORGO) shares soared 7.7% in the last trading session to close at $17.91. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 19.9% loss over the past four weeks.

Earlier this month, the company reported record quarterly revenues of $102.6 million in the first quarter of 2021. This might have driven the rally. The company’s efforts to develop its pipeline candidates, offering a portfolio of bioactive and acellular biomaterials products in wound care and surgical biologics, is also a positive.

Price and Consensus

Price Consensus Chart for ORGO
Price Consensus Chart for ORGO

This regenerative medicine company is expected to post quarterly earnings of $0.07 per share in its upcoming report, which represents a year-over-year change of +240%. Revenues are expected to be $105.2 million, up 52.6% from the year-ago quarter.

While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.

For Organogenesis, the consensus EPS estimate for the quarter has been revised 225% higher over the last 30 days to the current level. And a positive trend in earnings estimate revision usually translates into price appreciation. So, make sure to keep an eye on ORGO going forward to see if this recent jump can turn into more strength down the road.

The stock currently carries a Zacks Rank 2 (Buy). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Organogenesis Holdings Inc. (ORGO) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting